Maud Eline Ottenheijm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maud Eline Ottenheijm has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Nicolai Jacob Wewer Albrechtsen
Department of Clinical Biochemistry Copenhagen University Hospital – Bispebjerg and Frederiksberg Copenhagen Denmark
3 shared publications Andreas Bartholdy
Section of Epidemiology, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publicationsCharlotte M. Sørensen
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publications- Filip Krag Knop
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
2 shared publications - Jens Juul Holst
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
2 shared publications - Karina Banasik
Department of Obstetrics and Gynaecology, Copenhagen University Hospital Hvidovre, Denmark (K.B.).
2 shared publications
Latest Publications
- Open Access
Implications of recursive Bayesian Sensory Inference
In this article, we examine how the balance between velocity-based and position-based proprioceptive feedback influences state estimation during motor control. We introduce a computational model of arm state inference grounded in Bayesian sensory integration and compare its behaviour to findings from three classical sensorimotor studies. The model allows us to contrast the predicted behaviour of two proprioceptive configurations: one relying primarily on position signals and another relying primarily on velocity signals, reflecting the distinct contributions of type II and type Ia muscle spindle afferents. Our simulations show that a system with strong reliance on velocity-based feedback tends to represent movement relative to previously estimated positions. In a simulated reaching task with briefly presented offset visual feedback, such an Agent produces systematic endpoint errors even after visual feedback is removed. In contrast, an Agent relying mainly on positional feedback is able to correctly update its inferred hand position after visual feedback is removed, thereby limiting this type of biased endpoint errors. When biased visual feedback remains continuously available, or when muscle vibration is simulated, the two configurations produce very similar behaviour. These results indicate that markedly different assumptions about the weighting of positional and velocity proprioceptive cues can yield similar observable behaviour in some of the often-used experimental setups designed to probe state inference processes. This underscores the importance of carefully considering the composition of proprioceptive signals when building computational models and interpreting human sensorimotor experiments. We highlight the task conditions under which our model predicts clear behavioural differences arising from the relative contribution of velocity versus positional feedback. 1 Author summary: During motor control, the central nervous system tracks both the position and movement of our limbs. Even with our eyes closed, we can bring the tips of our index fingers together, a feat that depends on sensory signals from specialised receptors in our muscles. One set of these receptors is most sensitive to the rate of muscle lengthening, providing information about movement, while another set signals the muscle’s current length, giving us a sense of posture. There has so far been limited discussion of the extent to which these two feedback channels are used to augment one another. For example, signals about the rate of muscle lengthening reflect how our pose is changing from moment to moment, but it remains unknown to what extent the brain uses this information to update its estimate of limb position. In this study, we simulate three classical sensorimotor experiments while varying the precision of these two types of sensory feedback. Two simulations show that different assumptions can yield similar movement patterns, highlighting the need for caution when interpreting such experiments. The third suggests that movement-related feedback may contribute more to our sense of limb position than previously recognised.
Open AccessImplications of recursive Bayesian Sensory Inference
In this article, we examine how the balance between velocity-based and position-based proprioceptive feedback influences state estimation during motor control. We introduce a computational model of arm state inference grounded in Bayesian sensory integration and compare its behaviour to findings from three classical sensorimotor studies. The model allows us to contrast the predicted behaviour of two proprioceptive configurations: one relying primarily on position signals and another relying primarily on velocity signals, reflecting the distinct contributions of type II and type Ia muscle spindle afferents. Our simulations show that a system with strong reliance on velocity-based feedback tends to represent movement relative to previously estimated positions. In a simulated reaching task with briefly presented offset visual feedback, such an Agent produces systematic endpoint errors even after visual feedback is removed. In contrast, an Agent relying mainly on positional feedback is able to correctly update its inferred hand position after visual feedback is removed, thereby limiting this type of biased endpoint errors. When biased visual feedback remains continuously available, or when muscle vibration is simulated, the two configurations produce very similar behaviour. These results indicate that markedly different assumptions about the weighting of positional and velocity proprioceptive cues can yield similar observable behaviour in some of the often-used experimental setups designed to probe state inference processes. This underscores the importance of carefully considering the composition of proprioceptive signals when building computational models and interpreting human sensorimotor experiments. We highlight the task conditions under which our model predicts clear behavioural differences arising from the relative contribution of velocity versus positional feedback. 1 Author summary: During motor control, the central nervous system tracks both the position and movement of our limbs. Even with our eyes closed, we can bring the tips of our index fingers together, a feat that depends on sensory signals from specialised receptors in our muscles. One set of these receptors is most sensitive to the rate of muscle lengthening, providing information about movement, while another set signals the muscle’s current length, giving us a sense of posture. There has so far been limited discussion of the extent to which these two feedback channels are used to augment one another. For example, signals about the rate of muscle lengthening reflect how our pose is changing from moment to moment, but it remains unknown to what extent the brain uses this information to update its estimate of limb position. In this study, we simulate three classical sensorimotor experiments while varying the precision of these two types of sensory feedback. Two simulations show that different assumptions can yield similar movement patterns, highlighting the need for caution when interpreting such experiments. The third suggests that movement-related feedback may contribute more to our sense of limb position than previously recognised.
- Open Access
- 17 October 2025
- Published by Elsevier in NeuroImage
- Vol. 322, 121533
Paired-pulse TMS of premotor cortex produces non-linear suppressive effects on neural activity in the targeted network - a TMS-fMRI study
- 17 October 2025
- Published by Elsevier in NeuroImage
- Vol. 322, 121533
Open AccessPaired-pulse TMS of premotor cortex produces non-linear suppressive effects on neural activity in the targeted network - a TMS-fMRI study
- Open Access
- 23 July 2024
- Published by Springer Nature in Clinical Proteomics
- Vol. 21 (1) , 1-15
Proteomic profile and predictive markers of outcome in patients with subarachnoid hemorrhage
Background: The molecular mechanisms underlying development of posthemorrhagic hydrocephalus (PHH) following subarachnoid hemorrhage (SAH) remain incompletely understood. Consequently, treatment strategies tailored towards the individual patient remain limited. This study aimed to identify proteomic cerebrospinal fluid (CSF) biomarkers capable of predicting shunt dependency and functional outcome in patients with SAH in order to improve informed clinical decision making. Methods: Ventricular CSF samples were collected twice from 23 patients with SAH who required external ventricular drain (EVD) insertion (12 patients with successful EVD weaning, 11 patients in need of permanent CSF shunting due to development of PHH). The paired CSF samples were collected acutely after ictus and later upon EVD removal. Cisternal CSF samples were collected from 10 healthy control subjects undergoing vascular clipping of an unruptured aneurysm. All CSF samples were subjected to mass spectrometry-based proteomics analysis. Proteomic biomarkers were quantified using area under the curve (AUC) estimates from a receiver operating curve (ROC). Results: CSF from patients with SAH displayed a distinct proteomic profile in comparison to that of healthy control subjects. The CSF collected acutely after ictus from patients with SAH was moreover distinct from that collected weeks later but appeared similar in the weaned and shunted patient groups. Sixteen unique proteins were identified as potential predictors of shunt dependency, while three proteins were identified as potential predictors of functional outcome assessed six months after ictus with the modified Rankin Scale. Conclusions: We here identified several potential proteomic biomarkers in CSF from patients with SAH capable of predicting (i) shunt dependency and thus development of PHH and (ii) the functional outcome assessed six months after ictus. These proteomic biomarkers may have the potential to aid clinical decision making by predicting shunt dependency and functional outcome following SAH.
- 23 July 2024
- Published by Springer Nature in Clinical Proteomics
- Vol. 21 (1) , 1-15
Open AccessProteomic profile and predictive markers of outcome in patients with subarachnoid hemorrhage
Background: The molecular mechanisms underlying development of posthemorrhagic hydrocephalus (PHH) following subarachnoid hemorrhage (SAH) remain incompletely understood. Consequently, treatment strategies tailored towards the individual patient remain limited. This study aimed to identify proteomic cerebrospinal fluid (CSF) biomarkers capable of predicting shunt dependency and functional outcome in patients with SAH in order to improve informed clinical decision making. Methods: Ventricular CSF samples were collected twice from 23 patients with SAH who required external ventricular drain (EVD) insertion (12 patients with successful EVD weaning, 11 patients in need of permanent CSF shunting due to development of PHH). The paired CSF samples were collected acutely after ictus and later upon EVD removal. Cisternal CSF samples were collected from 10 healthy control subjects undergoing vascular clipping of an unruptured aneurysm. All CSF samples were subjected to mass spectrometry-based proteomics analysis. Proteomic biomarkers were quantified using area under the curve (AUC) estimates from a receiver operating curve (ROC). Results: CSF from patients with SAH displayed a distinct proteomic profile in comparison to that of healthy control subjects. The CSF collected acutely after ictus from patients with SAH was moreover distinct from that collected weeks later but appeared similar in the weaned and shunted patient groups. Sixteen unique proteins were identified as potential predictors of shunt dependency, while three proteins were identified as potential predictors of functional outcome assessed six months after ictus with the modified Rankin Scale. Conclusions: We here identified several potential proteomic biomarkers in CSF from patients with SAH capable of predicting (i) shunt dependency and thus development of PHH and (ii) the functional outcome assessed six months after ictus. These proteomic biomarkers may have the potential to aid clinical decision making by predicting shunt dependency and functional outcome following SAH.
- Open Access
- 5 June 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-10
Proteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem inflammatory syndrome in children
Multisystem inflammatory syndrome in children (MIS-C) is a severe disease that emerged during the COVID-19 pandemic. Although recognized as an immune-mediated condition, the pathogenesis remains unresolved. Furthermore, the absence of a diagnostic test can lead to delayed immunotherapy. Using state-of-the-art mass-spectrometry proteomics, assisted by artificial intelligence (AI), we aimed to identify a diagnostic signature for MIS-C and to gain insights into disease mechanisms. We identified a highly specific 4-protein diagnostic signature in children with MIS-C. Furthermore, we identified seven clusters that differed between MIS-C and controls, indicating an interplay between apolipoproteins, immune response proteins, coagulation factors, platelet function, and the complement cascade. These intricate protein patterns indicated MIS-C as an immunometabolic condition with global hypercoagulability. Our findings emphasize the potential of AI-assisted proteomics as a powerful and unbiased tool for assessing disease pathogenesis and suggesting avenues for future interventions and impact on pediatric disease trajectories through early diagnosis.
- 5 June 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-10
Open AccessProteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem inflammatory syndrome in children
Multisystem inflammatory syndrome in children (MIS-C) is a severe disease that emerged during the COVID-19 pandemic. Although recognized as an immune-mediated condition, the pathogenesis remains unresolved. Furthermore, the absence of a diagnostic test can lead to delayed immunotherapy. Using state-of-the-art mass-spectrometry proteomics, assisted by artificial intelligence (AI), we aimed to identify a diagnostic signature for MIS-C and to gain insights into disease mechanisms. We identified a highly specific 4-protein diagnostic signature in children with MIS-C. Furthermore, we identified seven clusters that differed between MIS-C and controls, indicating an interplay between apolipoproteins, immune response proteins, coagulation factors, platelet function, and the complement cascade. These intricate protein patterns indicated MIS-C as an immunometabolic condition with global hypercoagulability. Our findings emphasize the potential of AI-assisted proteomics as a powerful and unbiased tool for assessing disease pathogenesis and suggesting avenues for future interventions and impact on pediatric disease trajectories through early diagnosis.
- Open Access
- 6 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (8) , 1602-1615
Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study
Aims/hypotheses: Glucagon and glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon, and dual agonists of their receptors are currently being explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and MASLD. GLP-1 levels have been reported to be largely unaffected or even reduced in similar conditions. We investigated potential determinants of plasma proglucagon and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ~410,000 white participants to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Data on plasma levels of proglucagon estimated using Olink technology were available for a subset of the cohort (~40,000). We determined associations of glucagon receptor variants and proglucagon with BMI, type 2 diabetes and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated proglucagon predicts type 2 diabetes development. Results: Obesity, MASLD and type 2 diabetes were associated with elevated plasma levels of proglucagon independently of each other. Baseline proglucagon levels were associated with the risk of type 2 diabetes development over a 14 year follow-up period (HR 1.13; 95% CI 1.09, 1.17; n=1562; p=1.3×10−12). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of proglucagon (β 0.847; 95% CI 0.04, 1.66; n=17; p=0.04), and carriers of variants with a predicted frameshift mutation had higher levels of liver fat compared with the wild-type reference group (β 0.504; 95% CI 0.03, 0.98; n=11; p=0.04). Conclusions/interpretation: Our findings support the suggestion that glucagon receptor signalling is involved in MASLD, that plasma levels of proglucagon are linked to the risk of type 2 diabetes development, and that proglucagon levels are influenced by genetic variation in the glucagon receptor, obesity, type 2 diabetes and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Data availability: All coding is available through https://github.com/nicwin98/UK-Biobank-GCG Graphical
- 6 May 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (8) , 1602-1615
Open AccessDeterminants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study
Aims/hypotheses: Glucagon and glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon, and dual agonists of their receptors are currently being explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and MASLD. GLP-1 levels have been reported to be largely unaffected or even reduced in similar conditions. We investigated potential determinants of plasma proglucagon and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ~410,000 white participants to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Data on plasma levels of proglucagon estimated using Olink technology were available for a subset of the cohort (~40,000). We determined associations of glucagon receptor variants and proglucagon with BMI, type 2 diabetes and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated proglucagon predicts type 2 diabetes development. Results: Obesity, MASLD and type 2 diabetes were associated with elevated plasma levels of proglucagon independently of each other. Baseline proglucagon levels were associated with the risk of type 2 diabetes development over a 14 year follow-up period (HR 1.13; 95% CI 1.09, 1.17; n=1562; p=1.3×10−12). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of proglucagon (β 0.847; 95% CI 0.04, 1.66; n=17; p=0.04), and carriers of variants with a predicted frameshift mutation had higher levels of liver fat compared with the wild-type reference group (β 0.504; 95% CI 0.03, 0.98; n=11; p=0.04). Conclusions/interpretation: Our findings support the suggestion that glucagon receptor signalling is involved in MASLD, that plasma levels of proglucagon are linked to the risk of type 2 diabetes development, and that proglucagon levels are influenced by genetic variation in the glucagon receptor, obesity, type 2 diabetes and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Data availability: All coding is available through https://github.com/nicwin98/UK-Biobank-GCG Graphical
- Open Access
Determinants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank study
Aims/hypotheses: Glucagon and Glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon (gcg), and dual agonists of their receptors are currently explored for the treatment of obesity and steatotic liver disease. Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). It is unknown whether type 2 diabetes, obesity or MASLD causes hyperglucagonaemia or vice versa. We investigated potential determinants of plasma gcg and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ∼410,000 Caucasians to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Plasma levels of gcg estimated using Olink technology was available for a subset of the cohort (∼40,000). We determined associations between glucagon receptor variants and gcg with BMI, type 2 diabetes, and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated gcg predicts type 2 diabetes development. Results: Obesity, MASLD, and type 2 diabetes independently associated with elevated plasma levels of gcg. Baseline gcg levels were statistically significantly associated with the risk of type 2 diabetes development over a 14-year follow-up period (hazard ratio = 1.13; 95% confidence interval (CI) = 1.09, 1.17, p < 0.0001). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of gcg (β = 0.847; CI = 0.04, 1.66; p = 0.04), and carriers of variants with a predicted frameshift mutation had significantly higher levels of liver fat compared to wild-type controls (β = 0.504; CI = 0.03, 0.98; p = 0.04). Conclusions/interpretation: Our findings support that glucagon receptor signalling is involved in MASLD and type 2 diabetes, and that plasma levels of gcg are determined by genetic variation in the glucagon receptor, obesity, type 2 diabetes, and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Research in context: What is already known about this subject? Glucagon contributes to fasting hyperglycaemia in type 2 diabetes Hyperglucagonemia is often observed in metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and type 2 diabetes Glucagon/GLP-1 co-agonists have superior metabolic benefits compared to monoagonists What is the key question? What are key determinants of plasma proglucagon (gcg) and is elevated plasma gcg a cause or consequence (or both) of type 2 diabetes? What are the new findings? Plasma levels of gcg are increased in type 2 diabetes, MASLD and obesity independently of each other Increased plasma gcg associates with higher risk of type 2 diabetes development Glucagon signalling associates with hepatic fat How might this impact on clinical practice in the foreseeable future? Biased glucagon receptor-regulating agents may be beneficial in the treatment of obesity and MASLD.
Open AccessDeterminants of plasma levels of gcg and metabolic impact of glucagon receptor signalling – a UK Biobank study
Aims/hypotheses: Glucagon and Glucagon-like peptide-1 (GLP-1) are derived from the same precursor; proglucagon (gcg), and dual agonists of their receptors are currently explored for the treatment of obesity and steatotic liver disease. Elevated levels of endogenous glucagon (hyperglucagonaemia) have been linked with hyperglycaemia in individuals with type 2 diabetes but are also observed in individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). It is unknown whether type 2 diabetes, obesity or MASLD causes hyperglucagonaemia or vice versa. We investigated potential determinants of plasma gcg and associations of glucagon receptor signalling with metabolic diseases based on data from the UK Biobank. Methods: We used exome sequencing data from the UK Biobank for ∼410,000 Caucasians to identify glucagon receptor variants and grouped them based on their known or predicted signalling. Plasma levels of gcg estimated using Olink technology was available for a subset of the cohort (∼40,000). We determined associations between glucagon receptor variants and gcg with BMI, type 2 diabetes, and liver fat (quantified by liver MRI) and performed survival analyses to investigate if elevated gcg predicts type 2 diabetes development. Results: Obesity, MASLD, and type 2 diabetes independently associated with elevated plasma levels of gcg. Baseline gcg levels were statistically significantly associated with the risk of type 2 diabetes development over a 14-year follow-up period (hazard ratio = 1.13; 95% confidence interval (CI) = 1.09, 1.17, p < 0.0001). This association was of the same magnitude across strata of BMI. Carriers of glucagon receptor variants with reduced cAMP signalling had elevated levels of gcg (β = 0.847; CI = 0.04, 1.66; p = 0.04), and carriers of variants with a predicted frameshift mutation had significantly higher levels of liver fat compared to wild-type controls (β = 0.504; CI = 0.03, 0.98; p = 0.04). Conclusions/interpretation: Our findings support that glucagon receptor signalling is involved in MASLD and type 2 diabetes, and that plasma levels of gcg are determined by genetic variation in the glucagon receptor, obesity, type 2 diabetes, and MASLD. Determining the molecular signalling pathways downstream of glucagon receptor activation may guide the development of biased GLP-1/glucagon co-agonist with improved metabolic benefits. Research in context: What is already known about this subject? Glucagon contributes to fasting hyperglycaemia in type 2 diabetes Hyperglucagonemia is often observed in metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and type 2 diabetes Glucagon/GLP-1 co-agonists have superior metabolic benefits compared to monoagonists What is the key question? What are key determinants of plasma proglucagon (gcg) and is elevated plasma gcg a cause or consequence (or both) of type 2 diabetes? What are the new findings? Plasma levels of gcg are increased in type 2 diabetes, MASLD and obesity independently of each other Increased plasma gcg associates with higher risk of type 2 diabetes development Glucagon signalling associates with hepatic fat How might this impact on clinical practice in the foreseeable future? Biased glucagon receptor-regulating agents may be beneficial in the treatment of obesity and MASLD.